Repare Therapeutics Inc.
RPTX
$1.36
$0.118.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -96.45% | 822.93% | -28.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -96.45% | 822.93% | -28.31% |
| Cost of Revenue | 8.25% | -13.17% | -10.99% | 3.58% | -408.88% |
| Gross Profit | -20.45% | 7.03% | -719.50% | 174.31% | 1,149.68% |
| SG&A Expenses | -19.92% | -18.10% | -4.61% | 1.04% | 7.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.87% | -14.13% | -9.68% | 3.05% | 16.08% |
| Operating Income | 0.23% | 9.30% | -204.45% | 131.19% | -57.23% |
| Income Before Tax | -2.98% | 3.57% | -289.86% | 144.03% | -67.41% |
| Income Tax Expenses | -100.00% | 102.98% | -89.52% | -82.61% | -98.74% |
| Earnings from Continuing Operations | -2.29% | -82.24% | -191.09% | 137.67% | 11.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.29% | -82.24% | -191.09% | 137.67% | 11.46% |
| EBIT | 0.23% | 9.30% | -204.45% | 131.19% | -57.23% |
| EBITDA | 0.06% | 9.37% | -213.40% | 133.05% | -58.32% |
| EPS Basic | -1.38% | -80.75% | -188.69% | 137.49% | 11.79% |
| Normalized Basic EPS | -2.62% | 8.67% | -286.59% | 143.83% | -66.76% |
| EPS Diluted | -1.38% | -80.75% | -188.69% | 136.10% | 11.89% |
| Normalized Diluted EPS | -2.62% | 8.67% | -286.59% | 142.04% | -66.76% |
| Average Basic Shares Outstanding | 0.88% | 0.83% | 0.85% | 0.46% | 0.38% |
| Average Diluted Shares Outstanding | 0.88% | 0.83% | 0.85% | 4.72% | 0.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |